Lv21
180 积分 2025-03-15 加入
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
29天前
已完结
Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
30天前
已完结
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
1个月前
已完结
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
2个月前
已完结
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study
2个月前
已完结
Burden and Regional Disparities of MASH ‐Related Liver Cancer in the Asia‐Pacific Region From 1990 to 2023
2个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
2个月前
已完结
Biological gender difference of bile acid metabolism in susceptibility to cholelithiasis in patients with nonalcoholic fatty liver disease
2个月前
已完结
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
3个月前
已完结
FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid
3个月前
已完结
皖公网安备34019202002308
